ClinicalTrials.gg
CompletedNCT02134834Updated Dec 12, 2014

A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595

A Phase 1 interventional study of OP0595 and Placebo in Healthy Volunteers and Bacterial Infections, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 1 site in Australia. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-12.

Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Bacterial Infections with a site in Australia — 1 open to participants now, 1 under way, none of them phase 3. Bacterial Infections · Australia.

Enrollment
20th of 26
40 · median 65
Started
2014
the only one that year
Phase 1
21 of 29
none open now
Registered
13th of 29
by date

Among the 29 studies in Bacterial Infections with a site in Australia, this one is the 20th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2014, is one of 21 in phase 1, and was the 13th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

1 of the 29 studies in Bacterial Infections with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Bacterial Infections with a site in Australia, or all of them as a file.
02

Study summary

The objectives of this study are to assess the safety, tolerability and pharmacokinetic profile of OP0595 administered intravenously to healthy male, Caucasian, adult subjects at single escalating doses.

03

Conditions studied

  • Healthy Volunteers
  • Bacterial Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian males aged between 18 and 45 years (inclusive) at Screening
  • A (BMI) between 18.0 and 30.0 kg/m² (inclusive) at Screening
  • Good general health as determined by the Investigator based on medical history, physical examination, vital signs, 12-lead and clinical laboratory tests
  • Negative urine test for drugs of abuse and breath test for alcohol both at Screening and Day -1

Exclusion criteria

Exclusion Criteria:

  • Receipt of any agent or drug within four months before Screening
  • A history or current evidence of allergic symptoms such as bronchial asthma, drug-induced rash or urticaria
  • and/or allergy to drugs
  • Concurrent or history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, respiratory, psychiatric, neurologic and/or hematological disorders
  • A history of chronic or recurrent infections or current active infection
  • A recent history of surgery within three months prior to Screening, determined by the Investigator to be clinically relevant
  • A history or presence of
  • Donation of blood (or loss of blood) greater than 400 ml within three months before Screening
  • A history of smoking at any time within one year before Screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Ascending single dose of OP0595

    Drug: OP0595

  • Placebo comparator
    Normal Saline

    Drug: Placebo

Interventions

  • DrugOP0595

    Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

  • DrugPlacebo

    Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

06

What researchers measure

Primary outcomes

  1. Safety from baseline through the end of the study

    Number of patients with adverse events

    Time frame: Day 1 to Day 7

Secondary outcomes

  1. Plasma PK parameters of OP0595 and its metabolites

    Cmax, tmax, AUC0-last, AUC0-inf, Kel, T1/2, CLtot, Vdss

    Time frame: Day 1 to Day 2

  2. Urine PK parameters of OP0595 and its metabolites

    Ae, Ae0-t, Ae0-t/Dose, CLr

    Time frame: Day 1 to Day 2

07

Study locations

1 site
  • Perth,, Western Australia, Australia
08

References and documents

Publications

  • Mallalieu NL, Winter E, Fettner S, Patel K, Zwanziger E, Attley G, Rodriguez I, Kano A, Salama SM, Bentley D, Geretti AM. Safety and Pharmacokinetic Characterization of Nacubactam, a Novel beta-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02229-19. doi: 10.1128/AAC.02229-19. Print 2020 Apr 21. PubMed 32041717 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Aug 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2014
First posted
May 9, 2014
Start
May 2014
Primary completionActual
Aug 2014
CompletionActual
Nov 2014
Last update
Dec 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02134834
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Responsible party
Sponsor
First posted
May 9, 2014
Start date
May 2014
Primary completion
Aug 2014
Completion
Nov 2014
Last update
Dec 12, 2014

Study contacts

Mitsuharu Egawa
study chair · Meiji Seika Pharma Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nacubactam

Start the discussion